DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

May 1 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat first-quarter sales estimates helped by strong demand for its continuous glucose monitors (CGMs) used by patients with ...

Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

The accompanying press release dated May 1, 2025 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

DexCom develops and sells continuous glucose monitoring (CGM) systems, which help people with diabetes track their blood sugar levels in real time. Its flagship products include the Dexcom G6 and G7 ...

People with diabetes can use continuous glucose monitors (CGMs) to make tracking their blood sugar levels easier. Instead of drawing blood multiple times per day, a person continuously wears a sensor ...

VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...